Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that leverages its financial strength to beat the competition and two best left off your watchlist.
Two Stocks to Sell:
Monarch (MCRI)
Trailing 12-Month GAAP Operating Margin: 25.1%
Established in 1993, Monarch (NASDAQ: MCRI) operates luxury casinos and resorts, offering high-end gaming, dining, and hospitality experiences.
Why Do We Avoid MCRI?
- Annual revenue growth of 14.1% over the last five years was below our standards for the consumer discretionary sector
- Free cash flow margin is forecasted to grow by 1.4 percentage points in the coming year, potentially giving the company more chips to play with
- Improving returns on capital suggest management is identifying more profitable investments
At $115.25 per share, Monarch trades at 17.6x forward P/E. Dive into our free research report to see why there are better opportunities than MCRI.
Biogen (BIIB)
Trailing 12-Month GAAP Operating Margin: 12.3%
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Why Are We Cautious About BIIB?
- Sales tumbled by 3% annually over the last five years, showing market trends are working against it during this cycle
- Earnings per share have dipped by 10.6% annually over the past five years, which is concerning because stock prices follow EPS over the long term
- Eroding returns on capital suggest its historical profit centers are aging
Biogen’s stock price of $225.94 implies a valuation ratio of 17.1x forward P/E. Check out our free in-depth research report to learn more about why BIIB doesn’t pass our bar.
One Stock to Watch:
Mirion (MIR)
Trailing 12-Month GAAP Operating Margin: 6.9%
With its technology protecting workers in over 130 countries and equipment used in 80% of cancer centers worldwide, Mirion Technologies (NYSE: MIR) provides radiation detection, measurement, and monitoring solutions for medical, nuclear energy, defense, and scientific research applications.
Why Do We Watch MIR?
- Market share has increased this cycle as its 11.7% annual revenue growth over the last two years was exceptional
- Adjusted operating margin expanded by 13.3 percentage points over the last five years as it scaled and became more efficient
- Free cash flow margin increased by 13.7 percentage points over the last five years, giving the company more capital to invest or return to shareholders
Mirion is trading at $14.36 per share, or 23.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
